Cargando…
Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group
This is the first multi‐institutional retrospective survey of the long‐term outcomes of proton therapy (PT) for prostate cancer in Japan. This retrospective analysis comprised prostate cancer patients treated with PT at seven centers between January 2008 and December 2011 and was approved by each In...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852348/ https://www.ncbi.nlm.nih.gov/pubmed/29441697 http://dx.doi.org/10.1002/cam4.1350 |
_version_ | 1783306553270468608 |
---|---|
author | Iwata, Hiromitsu Ishikawa, Hitoshi Takagi, Masaru Okimoto, Tomoaki Murayama, Sigeyuki Akimoto, Tetsuo Wada, Hitoshi Arimura, Takeshi Sato, Yoshitaka Araya, Masayuki Mizoe, Jun‐etsu Gosho, Masahiko Nakamura, Katsumasa Shirato, Hiroki Sakurai, Hideyuki |
author_facet | Iwata, Hiromitsu Ishikawa, Hitoshi Takagi, Masaru Okimoto, Tomoaki Murayama, Sigeyuki Akimoto, Tetsuo Wada, Hitoshi Arimura, Takeshi Sato, Yoshitaka Araya, Masayuki Mizoe, Jun‐etsu Gosho, Masahiko Nakamura, Katsumasa Shirato, Hiroki Sakurai, Hideyuki |
author_sort | Iwata, Hiromitsu |
collection | PubMed |
description | This is the first multi‐institutional retrospective survey of the long‐term outcomes of proton therapy (PT) for prostate cancer in Japan. This retrospective analysis comprised prostate cancer patients treated with PT at seven centers between January 2008 and December 2011 and was approved by each Institutional Review Board. The NCCN classification was used. Biochemical relapse was based on the Phoenix definition (nadir + 2.0 ng/mL). Toxicities were evaluated with the Common Terminology Criteria for Adverse Events version 4.0. There were 215, 520, and 556 patients in the low‐risk, intermediate‐risk, and high‐risk groups, respectively. The median follow‐up period of surviving patients was 69 months (range: 7–107). Among all patients, 98.8% were treated using a conventional fractionation schedule and 1.2% with a hypofractionation schedule; 58.5% and 21.5% received neoadjuvant and adjuvant androgen deprivation therapy, respectively. The 5‐year biochemical relapse‐free survival (bRFS) and overall survival rates in the low‐risk, intermediate‐risk, and high‐risk groups were 97.0%, 91.1%, and 83.1%, and 98.4%, 96.8%, and 95.2%, respectively. In the multivariate analysis, the NCCN classification was a significant prognostic factor for bRFS, but not overall survival. The incidence rates of grade 2 or more severe late gastrointestinal and genitourinary toxicities were 4.1% and 4.0%, retrospectively. This retrospective analysis of a multi‐institutional survey suggested that PT is effective and well‐tolerated for prostate cancer. Based on this result, a multi‐institutional prospective clinical trial (UMIN000025453) on PT for prostate cancer has just been initiated in order to define its role in Japan. |
format | Online Article Text |
id | pubmed-5852348 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58523482018-03-22 Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group Iwata, Hiromitsu Ishikawa, Hitoshi Takagi, Masaru Okimoto, Tomoaki Murayama, Sigeyuki Akimoto, Tetsuo Wada, Hitoshi Arimura, Takeshi Sato, Yoshitaka Araya, Masayuki Mizoe, Jun‐etsu Gosho, Masahiko Nakamura, Katsumasa Shirato, Hiroki Sakurai, Hideyuki Cancer Med Clinical Cancer Research This is the first multi‐institutional retrospective survey of the long‐term outcomes of proton therapy (PT) for prostate cancer in Japan. This retrospective analysis comprised prostate cancer patients treated with PT at seven centers between January 2008 and December 2011 and was approved by each Institutional Review Board. The NCCN classification was used. Biochemical relapse was based on the Phoenix definition (nadir + 2.0 ng/mL). Toxicities were evaluated with the Common Terminology Criteria for Adverse Events version 4.0. There were 215, 520, and 556 patients in the low‐risk, intermediate‐risk, and high‐risk groups, respectively. The median follow‐up period of surviving patients was 69 months (range: 7–107). Among all patients, 98.8% were treated using a conventional fractionation schedule and 1.2% with a hypofractionation schedule; 58.5% and 21.5% received neoadjuvant and adjuvant androgen deprivation therapy, respectively. The 5‐year biochemical relapse‐free survival (bRFS) and overall survival rates in the low‐risk, intermediate‐risk, and high‐risk groups were 97.0%, 91.1%, and 83.1%, and 98.4%, 96.8%, and 95.2%, respectively. In the multivariate analysis, the NCCN classification was a significant prognostic factor for bRFS, but not overall survival. The incidence rates of grade 2 or more severe late gastrointestinal and genitourinary toxicities were 4.1% and 4.0%, retrospectively. This retrospective analysis of a multi‐institutional survey suggested that PT is effective and well‐tolerated for prostate cancer. Based on this result, a multi‐institutional prospective clinical trial (UMIN000025453) on PT for prostate cancer has just been initiated in order to define its role in Japan. John Wiley and Sons Inc. 2018-02-14 /pmc/articles/PMC5852348/ /pubmed/29441697 http://dx.doi.org/10.1002/cam4.1350 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Iwata, Hiromitsu Ishikawa, Hitoshi Takagi, Masaru Okimoto, Tomoaki Murayama, Sigeyuki Akimoto, Tetsuo Wada, Hitoshi Arimura, Takeshi Sato, Yoshitaka Araya, Masayuki Mizoe, Jun‐etsu Gosho, Masahiko Nakamura, Katsumasa Shirato, Hiroki Sakurai, Hideyuki Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group |
title | Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group |
title_full | Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group |
title_fullStr | Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group |
title_full_unstemmed | Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group |
title_short | Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group |
title_sort | long‐term outcomes of proton therapy for prostate cancer in japan: a multi‐institutional survey of the japanese radiation oncology study group |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852348/ https://www.ncbi.nlm.nih.gov/pubmed/29441697 http://dx.doi.org/10.1002/cam4.1350 |
work_keys_str_mv | AT iwatahiromitsu longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT ishikawahitoshi longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT takagimasaru longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT okimototomoaki longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT murayamasigeyuki longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT akimototetsuo longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT wadahitoshi longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT arimuratakeshi longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT satoyoshitaka longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT arayamasayuki longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT mizoejunetsu longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT goshomasahiko longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT nakamurakatsumasa longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT shiratohiroki longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup AT sakuraihideyuki longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup |